EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma
Por:
Khoubai, FZ, Calovoulos, A, Guillorit, H, Carrillo-Reixach, J, del Rio-Alvarez, A, Klein, P, Coma, MS, Avignon, C, Rousseau, B, Charrot, LM, Fedou, S, Dupuy, JW, Royo, L, Domingo-Sàbat, M, Thézé, N, Siegfried, G, Khatib, AM, Cairo, S, Indersie, E, Jain, BP, Trézéguet, V, Gontier, E, Lamoureux, F, Guettier, C, Mussini, C, Hagedorn, M, Armengol, C and Grosset, CF
Publicada:
23 feb 2026
Resumen:
Background EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood. Methods Potential correlation between EZH2 mRNA expression and clinical parameters was analyzed by computational and histological approaches using seven published transcriptomic datasets and tissue samples from patients with hepatoblastoma. EZH2 molecular function was deciphered using molecular approaches, gain- and loss-of-function genetic tools, proteomics, immunohistochemistry, pharmacological drugs, 2D cell- and spheroid-based assays, and four different animal models. Results Our data show that EZH2 mRNA expression correlated with poor prognostic markers such as tumor proliferation, and patients' death and shorter survival. EZH2 protein potentiated hepatoblastoma cell proliferation, migration, survival and cisplatin resistance through its histone methyltransferase activity by repressing DUSP5, and transcriptionally inducing DUSP9 and HMGCR. In vivo EZH2 sustained tumor cell proliferation, and tumor development and angiogenesis. The EZH2 inhibitor GSK126 synergized with HMG-CoA reductase inhibitor statins to eradicate hepatoblastoma cells in vitro and block tumor development in mice. This combination was also very effective on various hepatoblastoma and non-hepatoblastoma tumor cell lines. Conclusion Collectively, our data showed that the protein EZH2 promotes hepatoblastoma development, partly through its histone methyltransferase activity, by differentially modulating the expression of DUSP5, DUSP9 and HMGCR genes and by supporting the MAPK/ERK pathway in hepatoblastoma cells already displaying high Wnt signal activity. EZH2 inhibitors triggered lipid synthesis in hepatoblastoma cells and synergized with cholesterol-lowering statins to block hepatoblastoma development in vitro and in vivo. Therefore, we demonstrate the key role of EZH2 in proliferative hepatoblastoma and the therapeutic benefit of combining EZH2 inhibitor and statin to treat patients with cancer.
Filiaciones:
Khoubai, FZ:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Calovoulos, A:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Imaging Ctr, INSERM, CNRS,UMS 3420, F-33000 Bordeaux, France
Guillorit, H:
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Carrillo-Reixach, J:
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
Networking Biomed Res Ctr CIBER Hepat & Digest Dis, Barcelona, Spain
Klein, P:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Coma, MS:
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Avignon, C:
Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France
Rousseau, B:
Univ Bordeaux, Serv Commun Anim, Dept STS, Anim A2, F-33000 Bordeaux, France
Charrot, LM:
Univ Bordeaux, Serv Commun Anim, Dept STS, Anim A2, F-33000 Bordeaux, France
Fedou, S:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France
Dupuy, JW:
Univ Bordeaux, Bordeaux Proteome, F-33000 Bordeaux, France
Royo, L:
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
Domingo-Sàbat, M:
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
Thézé, N:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Siegfried, G:
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France
Khatib, AM:
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Univ Bordeaux, Xenofish Platform, F-33000 Bordeaux, France
Cairo, S:
XenTech SAS, Genopole Campus,1-3 impasse Alexis Trinquet, F-91000 Evry, France
Champ Oncol Inc, Baltimore, MD USA
Ist Ric Pediat, Padua, Italy
Indersie, E:
XenTech SAS, Genopole Campus,1-3 impasse Alexis Trinquet, F-91000 Evry, France
Jain, BP:
Mahatma Gandhi Cent Univ, Dept Zool, Motihari, Bihar, India
Trézéguet, V:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Gontier, E:
Univ Bordeaux, Bordeaux Imaging Ctr, INSERM, CNRS,UMS 3420, F-33000 Bordeaux, France
Lamoureux, F:
Nantes Univ, Team CHILD 9, INSERM, CNRS UMR 6075,UMR 1307,CRCI2NA, F-44000 Nantes, France
Guettier, C:
Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France
Mussini, C:
Bicetre Univ Hosp, AP HP, Dept Pathol, F-94275 Le Kremlin Bicetre, France
Hagedorn, M:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
:
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
Networking Biomed Res Ctr CIBER Hepat & Digest Dis, Barcelona, Spain
Grosset, CF:
Univ Bordeaux, INSERM, Biotherapy Genet Dis Inflammatory Disorders & Canc, BMGIC,U1035, F-33000 Bordeaux, France
Univ Bordeaux, Bordeaux Inst Oncol, INSERM, BRIC,U1312, F-33000 Bordeaux, France
Univ Bordeaux, MIRCADE Team, INSERM, U1312, 146 Rue Leo Saignat, F-33000 Bordeaux, France
Green Submitted, gold
|